<DOC>
	<DOCNO>NCT01372995</DOCNO>
	<brief_summary>The increase rate hospital-acquired infection antibiotic resistance major cause prolong ICU stay death hospitalize patient . The enormous impact ICU-related infection demand need cost-effective therapy rapidly implement improve patient immune response control infection . Unfortunately , little high-quality comparative effectiveness research perform micronutrient treatment regimens method decrease hospital-acquired infection critically ill patient . Critically ill medical surgical patient extremely high prevalence vitamin D insufficiency . We perform rigorous , double-blind , randomize , control , pilot clinical trial ventilator-dependent ICU patient test clinical/metabolic safety efficacy two dose oral high-dose vitamin D3 therapy versus standard therapy ( supplemental vitamin D ) . The primary endpoint test whether high-dose regimen [ either 50,000 100,000 international unit ( IU ) enteral vitamin D3 give daily 5 consecutive day ( total dose = 250,000 500,000 IU , respectively ) increase plasma 25 ( OH ) D concentration desirable range ( &gt; 30 ng/mL ) .</brief_summary>
	<brief_title>Vitamin D Ventilated ICU Patients</brief_title>
	<detailed_description>1 . We evaluate , 12 week , safety efficacy two high-dose vitamin D3 regimens severely ill ICU patient . Vitamin D placebo ( depend study arm ) give sequentially divide dose 5 day 2 . We explore whether vitamin D regimens capable increase production key antimicrobial peptide LL-37 hBD-2 ( substance produce body fight infection ) , blood lung . 3 . We determine whether high vitamin D level blood associate decrease hospital infection rate complication high-risk ICU patient respiratory failure . Study Design : Enrollment goal 36 patient . Once consent obtain subject randomly assign one three study group . Each group consist 12 patient enteral access ; placebo arm , arm subject receive 50,000 IU Vitamin D 5 day , third arm subject receive 100,000 IU Vitamin D 5 day . Methods : Baseline blood sample ( 25-hydroxyvitamin D , vitamin D binding protein , ionized calcium , LL-37 , hBD-2 ) take study day 7,14,21,28,84 day . On study day 1 8 , LL-37 , hBD-2 , cathelicidin BAL fluid also analyze . Patients give either placebo , Vitamin D3 50,000 IU x 5 day ( total 250,000 IU ) Vitamin D3 100,000 IU x 5 day ( total 500,000 IU ) intention treat model . Baseline data patient include demographic , laboratory , document infection , severity illness score ( APACHE II ) organ dysfunction score ( SOFA ) collect . ELISA assay serum BAL perform .</detailed_description>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Receiving care intensive care unit ( ICU ) Age great 18 year Expected require mechanical ventilation least 72 hour entry Expected survive remain ICU least 96 hour study entry To enable delivery study drug , subject enteral access place deem able tolerate enteral drug administration Inability obtain decline informed consent subject and/or legally authorize representative Pregnancy Ongoing shock Current hypercalcemia ( albumincorrected serum calcium &gt; 10.8 mg/dL ionized calcium &gt; 5.2 mg/dL ) History therapy highdose vitamin D treat vitamin D deficiency within previous 6 month History disorder associate hypercalcemia ; history cancer history hypercalcemia within past 1 year , hyperparathyroidism , sarcoidosis , nephrolithiasis ] Chronic renal dysfunction require chronic dialysis Known history cirrhosis History AIDS The patient receive investigational drug within 60 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>critical care</keyword>
	<keyword>nosocomial infection</keyword>
	<keyword>antiAntimicrobial peptide expression</keyword>
	<keyword>LL-37</keyword>
	<keyword>hBD-2</keyword>
	<keyword>cathelicidin</keyword>
	<keyword>microbial peptide</keyword>
</DOC>